Company Information
CIN
Status
Date of Incorporation
28 June 1985
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 August 2023
Paid Up Capital
498,866,990
Authorised Capital
800,000,000
Directors
Milind Shripad Sarwate
Director/Designated Partner
about 2 years ago
about 2 years ago
Kausalya Santhanam
Director/Designated Partner
over 2 years ago
over 2 years ago
Sharat Pandu Rang Narasapur
Director/Designated Partner
over 2 years ago
over 2 years ago
Neeraj Bharadwaj
Director/Designated Partner
over 2 years ago
over 2 years ago
Rahul Nirmal Mukim
Director/Designated Partner
over 2 years ago
over 2 years ago
Manish Gupta
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Kamal Kishore Sharma
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Patri Venkat Raghavendra Rao
Manager/Secretary
over 3 years ago
over 3 years ago
Fabian Martin Kausche
Director/Designated Partner
almost 5 years ago
almost 5 years ago
Gregory John Andrews
Director/Designated Partner
almost 5 years ago
almost 5 years ago
Arun Kumar Pillai
Director/Designated Partner
almost 6 years ago
almost 6 years ago
K R Ravishankar
Director/Designated Partner
almost 6 years ago
almost 6 years ago
Krunal Shashiraj Shah
Nodal Officer
about 6 years ago
about 6 years ago
Gopakumar G Nair
Director
about 6 years ago
about 6 years ago
Shankarlal Devendra .
Director
about 9 years ago
about 9 years ago
Rajakumar Ec Konduru
Director
about 9 years ago
about 9 years ago
Narendra Mairpady
Director
about 10 years ago
about 10 years ago
Ramanujam Kannan
Director
over 16 years ago
over 16 years ago
Past Directors
Hari Babu Bodepudi
Additional Director
over 2 years ago
over 2 years ago
Rajaram Narayanan
Director
over 3 years ago
over 3 years ago
Gautam Kumar Das
Managing Director
over 12 years ago
over 12 years ago
Preetham Hebbar
Company Secretary
over 12 years ago
over 12 years ago
Vinayak Hegde
Company Secretary
about 14 years ago
about 14 years ago
Koduru Rama Narasinha Moorthy
Additional Director
about 15 years ago
about 15 years ago
Joe Thomas
Director
over 16 years ago
over 16 years ago
Pallipuram Mathai Thampi
Director
about 17 years ago
about 17 years ago
Balasubramanian M
Director
about 18 years ago
about 18 years ago
Bina Sanjeev Shah
Director
over 20 years ago
over 20 years ago
Jagannath Nanjundiah Sulur
Director
about 22 years ago
about 22 years ago
Aditya Rajen Desai
Director
about 22 years ago
about 22 years ago
Bharat Bachubai Merchant
Director
about 22 years ago
about 22 years ago
Laxminarayan Narasinh Bhat
Managing Director
about 22 years ago
about 22 years ago
Patents
The present invention discloses a novel a process for the preparation of (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2-(I-tetrahydropyrimid-2-onyl)-3-methylbutanoyl)-amino-l,6-diphenylhexane of formula I comprising condensing N-[(lS,2S,4S)-4-amino-2-hydroxy-5-phenyl-l-(phenylmethyl)pentyl]-2-(2,6-dim...
The present invention relates to a novel, cost-effective process for the preparation of an anti-parasitic drug febantel of formula I involving a novel intermediate.
The present invention relates to a new method for preparing 4,4"-(l-methyl-1,2-ethandiyl)-bis-(2,6-piperazinedione) of formula (I) or its enantiomers. More specifically this invention relates to a new process for preparing 4,4"-( 1-methyl-1,2-ethandiyl)-bis-(2,6-piperazinedione), which gives better yield and purity ...
The present invention discloses a novel, cost-effective process for the preparation of an Oxyclozanide. Specifically, it relates to the process for the preparation of anthelmintic drug. The process comprises a) conversion of 3,5,6- trichlorosalicylic acid to 3,5,6-trichloro-2-hydroxybenzoyl chloride with thionyl chl...
The present invention relates to a novel process for preparing an antiretroviral drugl,3-thiazol-5-yImethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2- {[methyl({ [2-(propan-2-yl)-1,3-thiazol-4-yl]methyl })carbamoyI] amino}butanamido]-l,6-diphenylhexan-2-yl]carbamatecommonly known as Ritonavir of formula I, which co...
The present invention discloses a novel, cost-effective process for preparing psychostimulant drug cytidinediphosphate-choline (CDP-Choline) commonly known as citicoline. The process comprises reacting cytidine 5"-monophosphate with morpholine in presence of a coupling reagent and an organic solvent to form morpholi...
The present invention discloses a novel, cost-effective process for
preparation of a 2-cyclohexylcarbonyl-4-oxo-l,2,3,6,7,l 1b-hexahydro-4H-
pyrazino[2,l-a]isoquinoline formula I, which comprises: acylation of 4-oxo-
1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinoline with
cyclohexanoylchloride in presence of...
The present invention relates to a novel process for the preparation of triaryl phosphite, specifically it relates to the process for the preparation of tris (2,4 -di-tert-butyl phenyl) phosphite of formula I, an antioxidant.
The present invention relates to a novel, cost-effective process for preparation of an anthelmintic drug. Specifically, it relates to a process for the preparation of l-(4-Isothiocyanatophenoxy)-4-nitrobenzene of formula I, commonly known as Nitroscanate.
The present invention relates to a novel process for preparation of 5-methyl-2-pentylphenol and its purification.
The present invention relates to a novel process for the preparation of a non-steroidal anti-inflammatory drug, commonly known as carprofen of formula I.
The present invention discloses a novel, cost-effective one pot process for preparation of phenyl butyric acid of formula I by condensing phenyl ethyl bromide with diethyl malonate in presence of base and catalyst; insitu hydrolyzing the diethyl (2-phenyIethyl) malonate using a base to form diacid; and further decar...
The present invention relates to a novel, cost-effective process for preparation of an anthelmintic drug. Specifically, it relates to a process for the preparation of 4-amino-6-(trichloroethenyl)-l,3-benzenedisulfonamide of formula I, commonly known as Chlorsulon.
The present invention discloses a novel, cost-effective process for preparation of a diazoamino benzene compound. Specifically, it relates to the process for the preparation of diminazene diaceturate. The process comprises a) converting p-nitro benzoic acid of formula VII into p-nitro benzamide of formula VI; b...
The present invention discloses a novel, cost-effective process for preparation of a diazoamino benzene compound. Specifically, it relates to the process for the preparation of diminazene diaceturate. The process comprises a) converting p-nitro benzoic acid of formula VII into p-nitro benzamide of formula VI; b) con...
The present invention relates to a novel, cost-effective process for the preparation of Sterile Meropenem Trihydrate, which is prepared by a) condensation of l-Azabicyclo[3.2.0]hepta-2-ene-2-carboxylic acid, 3-[(diphenoxyphosphinyl)oxy]-6-(l-hydroxyethyl)-4-methyl-7-oxo-(4-nitrobenzyl) methyl ester,[4R-[4a,5b,6b(R*)...
The present invention relates to a novel process for the preparation of 1 β-methylcarbapenem antibiotic, Ertapenem of formula I. The process comprises deprotection of monoprotected Ertapenem acid or its monosodium salt by 2.5% Pd/C to obtain Ertapenem monosodium.
The present invention relates to a novel, cost-effective process for the preparation of a cholelitholytic agent Ursodeoxycholic acid of formula I, comprising reducing 7-ketolithocholic acid of formula II using a reducing agent and an alkoxide in presence of a solvent to obtain crude Ursodeoxycholic acid; and purifyi...
The present invention discloses a novel, cost-effective process for preparation of [R-[R*,R*-(E)]]-2,2'-(l,8-dioxo-4-octene-l,8-diyl) bis(oxy-3,1 -propanediyl) bis(l ,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1 -[(3,4,5-trimethoxyphenyl)- methyl] isoquinolinium) dichloride, commonly known as mivacurium chloride, which...
The present invention discloses a novel process for the preparation of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-l,6-diphenylhexane hydrochloride of formula II, which is a key intermediate in the preparation of cobicistat, a drug under experimental investigation for use in the treatment of infe...
The present invention provides an improved process for preparation of Firocoxib of Formula I. Further, the present invention relates to novel process for the preparation of crystalline polymorphic form B of Firocoxib of Formula I.
The present invention relates to a novel, cost-effective process for the preparation of 1-hydrazinophthalazine hydrochloride of formula I, which involves the preparation of 1-chlorophthalazine using phthalazinone and phosphorous oxychloride, further reacting with hydrazine hydrate and an acid followed purification o...
The present invention discloses a novel process for the preparation of ethyl 3-[5-(3-chloro-2-fluorobenzyl)-2.4-dimethoxy phenyl]-3-oxopropanoate of formula II, which is a key intermediate in the preparation of Eivitegravir, a drug used in the treatment of infection with the human immunodeficiency virus (HIV).
...
The present invention relates to a facile and cost-effective process for the preparation of ether derivatives of dihydroartemisinin. The present invention farther enables preparation of pure ß-ether derivatives of dihydroartemisinin, commonly known as Artemether, the methyl ether derivative and Arteether, the ethyl ...
The present invention relates to a novel process for the preparation of Succinylcholine Chloride, a pharmaceuticaliy active compound used as skeletal muscle relaxant which comprises condensing succinic anhydride with N,N-Diemthylaminoethanol using a catalyst in presence of a solvent to form bis[2-(dimethylamino)ethy...
The present invention relates to a novel, cost-effective process for preparation of an Antioxidant bis (2,4-dicumyIphenyI) pentaerythritol diphosphite commonly known as Doverphos-S-9228 of formula I by condensing pentaerythritol with 2,4-dicumylphenol using a reagent and catalyst in presence of a solvent.
...
The present invention discloses a novel, cost-effective process for preparation of 4-(propylthio)benzene-l,2-diamine of formula II, a key intermediate of an anti-parasite bulk drug albendazole.
The present invention relates to a novel process for preparation of 2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-1.4-naphthoquinone commonly known as Buparvaquone of formula I without using silver nitrate as a catalyst.
The present invention discloses a novel, cost-effective process for preparation of a benzimidazole carbamates compound. Specifically, it relates to the process for the preparation of anti-parasite bulk drug albendazole. The process comprises a) thiocyanating 2-nitroaniline of formula VI with ammonium thiocyanated in...
The present invention discloses a method for preparing Triclabendazole comprising
condensing N-(4,5-dichloro-2-nitrophenyl)acetamide with 2,3-dichlorophenol to
obtain 4-chloro-5(2,3-dichlorophenoxy)-2-nitrophenyl acetamide and it to obtain 4-
chloro-5(2,3-dichlorophenoxy)-2-nitroaniline; reducing 4-chloro-5(2,3-d...
The present invention relates to a novel process for the preparation of an anaesthetic drug Midazolam of formula I which comprises reductive amination of l-{4-chloro-2-[2-(2-fluorophenyI)-l,3-dithioIan-2-yl]phenyl}-5-methyl-lH-imidazole-5-carboxaldehyde using a reducing agent and ammonia in an alcoholic solvent to o...
The present invention relates to a novel process for the preparation of cilastatin of formula I by the condensation of 7-chloro-2-[[(lS)-2,2-dimethylcyclopropane] carboxamide]-2-heptenoic acid with L-cysteine in presence of l,8-diazabicyclo[4.3.0]undec-7-ene (DBU) and a solvent.
The present invention relates to a novel cost effective and commercially viable process for the preparation of pure crystalline Imipenem monohydrate by dissolving crude imipenem in carbonated water and morpholinopropane sulphonic acid (MOPS); treating with carbon, filering and precipitating by an organic solvent.
...
The present invention disclosed a process for the preparation of etomidate in which the R-(+)-phenylethylamine is reacted with ethyl chloroacetate in absence of a solvent to give R-(+)-N-[(ethoxycarbonyl)methyl]-l-phenylethylamine, which is formylated to give R-(+)-(N-formyl-N-[(ethoxycarbonyl)methyl]-l-phenylethyla...
The present invention discloses a novel, cost-effective process for preparation of a 4- oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino-[2,1-a]isoquinoline derivatives. Specifically it discloses a process for the preparation of anthelmenthic drug praziquantel incorporating a novel intermediate 2-[(2,2-dimethoxyethyl)benzyl ...
Disclosed herin, an improved process for producing beta-thymidine from 5-methyl uridine.The process comprising cyclizing 5-methyl urdine to 2.2' anhydrothymidine, hydrohalogenating 2.2'-anhydrothmidine to from 2'halo-2'deoxy-5-methyl uridine resultant crude beta-thymidine to obtain pure beta-thymidine
...
Disclosed herein is an economical and enantioselective process for producing (S)-1-(2-amino-5-chlorophenyl)-1-(trifluoromethyl)-3-cyclopropyl-2-propane-1-ol comprising reacting 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroacetophenone, chiral zinc alkoxide and cyclopropyl acetylene followed by isolation and purificatio...
Novel Intermediates, Process For Preparing The Same And Use Thereof In Production Of Doxercalciferol
The present invention provides novel intermediates for producing pure doxercalciferol. Further, the process for producing said intermediates and use thereof in production of doxercalciferol is also disclosed herein.
The present invention discloses a stable amorphous form of Rifaximin characterised by having X-ray powder diffraction pattern as given in figure 1, having a 2θ peaks at 7.2 and having moisture content in the range of 3% to 4% preferably, 3.4% to 3.7%. This invention also discloses a novel process for its preparation...
The present invention relates to a novel in-situ process for preparing l-(6-methylpyridin-3-yl)-2-[(4-(methylsulphonyl)phenyl]ethanone of the formula I,which eliminates the isolation of ketosulfide stage and avoids use of methanesulfonic acid and alkali metal tungstate for the oxidation of ketosulfide to ketosulfone...
The present invention discloses a process for preparation of 1,3-Bis[3-(4,5-dihydro-lH-imidazol-2-yl)phenyl]urea dipropionate. The process comprises reacting 3-amino benzonitrile with carbonyl diimidazole in presence of an organic base and solvent to form l,3-Bis-(3-cyano-phenyl)-urea; cyclizing l,3-Bis-(3-cyano-phe...
The present invention discloses a novel, facile and cost-effective process for the preparation of (2E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile of formula II, which is a key intermediate in the preparation of an antiretroviral drug Rilpivirine.
The present invention discloses a novel process for the preparation of ethyl 3-{5-(3-chloro- 2-fluorobenzyl)-2,4-dimethoxy phenylj-3-oxopropanoate, which is a key intermediate in the preparation of Elvitegravir, a drug under experimental investigation for use in the treatment of infection with the human immunodefici...
The present invention discloses a novel, facile and cost-effective process for the preparation of an antihypertensive agent labetalol hydrochloride of formula I which comprises condensing l-methyl-3-phenyl propylamine with 5-bromo acetyl salicylamide in presence of solvent and hydrochloric acid to obtain 2-hydroxy-5...
The present invention relates to a novel in-situ process for preparation of . 2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-l,4-naphthoquinone commonly known as Buparvaquone of formula I. The buparvaquone is obtained in pure trans form by purification with a ketonic solvent.
The present invention relates to a novel process for preparing an antimalarial drug 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4- chlorobenzylidene)-9H-fluoren-4-yl]ethanolcommonly known as Lumifantrine of formula I, which comprises:chloroacylating 2,7-dichloro-9H-fluorene using chloroaetyl chloride and a catalyst in ...
The present invention relates to a novel process for preparing (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid of formula I, which avoids the isomerisation of cis-isomers.
The present invention relates to a novel crystalline form of 1-methylcarbapenem antibiotic, Ertapenem monosodium. The process comprises isolation of monoprotected Ertapenem acid or its monosodium salt and further deprotection to obtain Ertapenenm monosodium.
The present invention relates to a novel process for preparing 4-[3-[[2-Hydroxy-2-(4-hydroxyphenyl)ethyl] amino] butyl]phenol hydrochloride of formula I.
The present invention relates to a new amorphous form of tetrakis-(2,4-di-t-butylphenyl)-4,4"-biphenylene diphosphonite and a process of its preparation.
The present invention relates to a novel process for the preparation of triaryl phosphite, specifically it relates to the process for the preparation of tris (2,4 -di-tert-butyl phenyl) phosphite of formula I, an antioxidant.
The present invention relates to a novel process for the preparation of an anaesthetic drug Midazolam of formula I which comprises reductive amination of l-{4-chloro-2-[2-(2-fluorophenyl)-l,3-dithiolan-2-yl]phenyl}-5-methyl-lH-imidazole-5-carboxaldehyde using a reducing agent and ammonia in an alcoholic solvent to o...
The present invention discloses a novel, cost-effective process for preparation of sodium phenyl butyrate by treating a solution of a sodium salt of weak acid with phenyl butyric acid in an organic solvent in presence of a base under inert atmosphere.
The present invention relates to a novel, cost-effective and simple process for commercial scale production of methoxsalen which obviates the use of column chromatography for purification of dealkylated mass obtained from Ammi majus plant extract to obtain purified dealkylated mass enriched with methoxsalen and xant...
The present invention relates to a novel process for the preparation of 1-methylcarbapenem antibiotic, Ertapenem of formula I. The process comprises isolation of monoprotected Ertapenem acid or its monosodium salt and further deprotection to obtain Ertapenem monosodium.
The present invention relates to a facile and cost-effective process for the preparation of ether derivatives of dihydroartemisinin. The present invention further enables preparation of pure β-ether derivatives of dihydroartemisinin free from ά-isomer, commonly known as Artemether, the methyl ether derivative and Ar...
Abstract
The present invention discloses a novel, cost-effective process for the preparation of crystalline polymorphic Albendazole Form-I. The process comprises drying the wet albendazole having mixture of polymorphic forms under vacuum; heating and cooling to get pure crystalline Albendazole Form-1.
...
The present invention discloses a novel, cost-effective process for preparation of [R-[R*,R*-(E)]]-2,2"-(1,8-dioxo-4-octene-1,8-diyl) bis(oxy- 3,1 -propanediyl) bis( 1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1 -[(3,4,5- trimethoxyphenyl)- methyl] isoquinolinium) dichloride, commonly known as mivacurium chloride. The...
Registered Trademarks
[Class : 44] Veterinary Services, Agriculture, Horticulture And Forestry Services
[Class : 31] Food Stuff For Animals
[Class : 5] Medicinal, Nutritional And Pharmaceutical Preparations And Substances; Veterinary And Sanitary Preparation
View +35 more Brands for Sequent Scientific Limited.
Charges
28 September 2019
Icici Bank Limited
38 Crore
28 September 2019
Icici Bank Limited
25 Crore
14 March 2019
Indusind Bank Ltd.
50 Crore
10 October 2018
Rbl Bank Limited
63 Crore
08 July 2015
Rbl Bank Limited
18 Crore
09 October 2014
The Ratnakar Bank Limited
23 Crore
29 August 2016
Rbl Bank Limited
11 Crore
12 January 2016
Rbl Bank Limited
65 Crore
22 September 2014
Rbl Bank Limited
91 Crore
04 September 2015
Yes Bank Limited
100 Crore
16 June 2012
Housing Development Finance Corporation Limited
8 Crore
02 January 2000
State Bank Of Indore
30 Lak
02 January 2006
State Bank Of India
211 Crore
26 August 2008
Technology Development Board
4 Crore
10 December 2009
Corporation Bank - Consortium Leader
240 Crore
31 March 2015
Rbl Bank Limited
50 Crore
05 November 2012
Housing Development Finance Corporation Limited
98 Crore
13 January 2012
Central Bank Of India
45 Crore
10 May 2011
Central Bank Of India
35 Crore
31 October 2007
State Bank Of Indore
3 Crore
24 February 2011
Corporation Bank
7 Crore
16 February 2012
Corporation Bank
80 Crore
30 October 2010
State Bank Of Mysore
20 Crore
23 August 2007
State Bank Of Hyderabad
35 Crore
31 December 2009
State Bank Of Hyderabad And Five Other Banks
154 Crore
01 July 2011
State Bank Of Hyderabad
25 Crore
25 March 2011
State Bank Of Hyderabad
10 Crore
10 February 2009
Andhra Bank
40 Crore
20 August 2009
Andhra Bank
3 Crore
10 February 2009
Andhra Bank
45 Crore
15 November 2006
State Bank Of India
6 Crore
02 June 2006
State Bank Of India
3 Crore
04 March 2009
Axis Bank Limited
1 Crore
13 April 2010
State Bank Of Indore
13 Crore
15 January 2010
Bank Of India
20 Crore
09 July 2002
The Thane Janata Sahakari Bank Limited
1 Crore
10 July 2002
The Thane Janata Sahakari Bank Limited
1 Crore
30 September 2008
Union Bank Of India
1 Crore
28 December 2007
Union Bank Of India Limited
2 Crore
28 December 2007
Union Bank Of India Limited
5 Crore
30 September 2008
Union Bank Of India
3 Crore
25 September 2006
Hdfc Bank Limited
15 Crore
09 July 2002
Indian Overseas Bank
1 Crore
10 July 2002
Indian Overseas Bank
1 Crore
28 September 2019
Others
0
28 September 2019
Others
0
22 September 2014
Others
0
10 October 2018
Others
0
14 March 2019
Others
0
15 November 2006
State Bank Of India
0
10 July 2002
The Thane Janata Sahakari Bank Limited
0
29 August 2016
Others
0
02 June 2006
State Bank Of India
0
09 July 2002
The Thane Janata Sahakari Bank Limited
0
10 July 2002
Indian Overseas Bank
0
02 January 2006
State Bank Of India
0
12 January 2016
Rbl Bank Limited
0
04 September 2015
Yes Bank Limited
0
09 October 2014
The Ratnakar Bank Limited
0
05 November 2012
Housing Development Finance Corporation Limited
0
16 June 2012
Housing Development Finance Corporation Limited
0
25 March 2011
State Bank Of Hyderabad
0
30 October 2010
State Bank Of Mysore
0
15 January 2010
Bank Of India
0
10 February 2009
Andhra Bank
0
30 September 2008
Union Bank Of India
0
13 April 2010
State Bank Of Indore
0
23 August 2007
State Bank Of Hyderabad
0
24 February 2011
Corporation Bank
0
31 March 2015
Rbl Bank Limited
0
10 May 2011
Central Bank Of India
0
01 July 2011
State Bank Of Hyderabad
0
16 February 2012
Corporation Bank
0
08 July 2015
Rbl Bank Limited
0
10 December 2009
Corporation Bank - Consortium Leader
0
25 September 2006
Hdfc Bank Limited
0
31 December 2009
State Bank Of Hyderabad And Five Other Banks
0
20 August 2009
Andhra Bank
0
04 March 2009
Axis Bank Limited
0
13 January 2012
Central Bank Of India
0
10 February 2009
Andhra Bank
0
30 September 2008
Union Bank Of India
0
09 July 2002
Indian Overseas Bank
0
26 August 2008
Technology Development Board
0
28 December 2007
Union Bank Of India Limited
0
28 December 2007
Union Bank Of India Limited
0
31 October 2007
State Bank Of Indore
0
02 January 2000
State Bank Of Indore
0
28 September 2019
Others
0
28 September 2019
Others
0
22 September 2014
Others
0
10 October 2018
Others
0
14 March 2019
Others
0
15 November 2006
State Bank Of India
0
10 July 2002
The Thane Janata Sahakari Bank Limited
0
29 August 2016
Others
0
02 June 2006
State Bank Of India
0
09 July 2002
The Thane Janata Sahakari Bank Limited
0
10 July 2002
Indian Overseas Bank
0
02 January 2006
State Bank Of India
0
12 January 2016
Rbl Bank Limited
0
04 September 2015
Yes Bank Limited
0
09 October 2014
The Ratnakar Bank Limited
0
05 November 2012
Housing Development Finance Corporation Limited
0
16 June 2012
Housing Development Finance Corporation Limited
0
25 March 2011
State Bank Of Hyderabad
0
30 October 2010
State Bank Of Mysore
0
15 January 2010
Bank Of India
0
10 February 2009
Andhra Bank
0
30 September 2008
Union Bank Of India
0
13 April 2010
State Bank Of Indore
0
23 August 2007
State Bank Of Hyderabad
0
24 February 2011
Corporation Bank
0
31 March 2015
Rbl Bank Limited
0
10 May 2011
Central Bank Of India
0
01 July 2011
State Bank Of Hyderabad
0
16 February 2012
Corporation Bank
0
08 July 2015
Rbl Bank Limited
0
10 December 2009
Corporation Bank - Consortium Leader
0
25 September 2006
Hdfc Bank Limited
0
31 December 2009
State Bank Of Hyderabad And Five Other Banks
0
20 August 2009
Andhra Bank
0
04 March 2009
Axis Bank Limited
0
13 January 2012
Central Bank Of India
0
10 February 2009
Andhra Bank
0
30 September 2008
Union Bank Of India
0
09 July 2002
Indian Overseas Bank
0
26 August 2008
Technology Development Board
0
28 December 2007
Union Bank Of India Limited
0
28 December 2007
Union Bank Of India Limited
0
31 October 2007
State Bank Of Indore
0
02 January 2000
State Bank Of Indore
0
Documents
Form DIR-12-09012021_signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-29122020
Form DIR-12-29122020
Interest in other entities;-29122020
Optional Attachment-(1)-29122020
Form MGT-14-01122020-signed
Form DIR-12-12112020_signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-11112020
Interest in other entities;-11112020
Optional Attachment-(1)-11112020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-10112020
Altered articles of association-10112020
Form AOC-4(XBRL)-14102020-signed
Form MGT-14-06102020-signed
Optional Attachment-(2)-23092020
Optional Attachment-(3)-23092020
Optional Attachment-(1)-23092020
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-23092020
Optional Attachment-(4)-23092020
Altered articles of association-16092020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-16092020
Form DIR-12-10092020_signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-09092020
Interest in other entities;-09092020
Notice of resignation;-09092020
Evidence of cessation;-09092020
Form MGT-15-08092020_signed
Optional Attachment-(1)-07092020
Form DIR-12-07092020_signed
Evidence of cessation;-05092020
